EU Weighs New Rules to Cut Dependence on Chinese and Indian API Suppliers

Europe's pharmaceutical supply chain is facing another round of policy pressure. Following May's Critical Medicines Act agreement, EU lawmakers are reportedly weighing parallel rules for the chemicals sector aimed at cutting dependence on Chinese and Indian active pharmaceutical ingredient suppliers. Sandoz has already pressed Brussels to investigate Chinese antibiotic ingredient imports. For buyers and traders in the API and pharmaceutical intermediates space, this signals a shift that could reshape sourcing patterns across the continent.

Why the EU Is Targeting API Supply Chains

Europe's reliance on Chinese and Indian manufacturers for active pharmaceutical ingredients has been a known vulnerability for years. The Critical Medicines Act laid the groundwork by identifying medicines considered essential to public health and pushing for more diversified, resilient supply.

The reported chemicals sector rules would extend that logic further upstream. Rather than focusing only on finished medicines, regulators appear ready to address the raw material and intermediate stage where much of the actual dependence sits.

Sandoz and the Antibiotic Ingredient Question

Sandoz's push for Brussels to probe Chinese antibiotic ingredient imports adds a concrete example to what has largely been a policy conversation until now. Antibiotics sit near the center of this debate because so much of the world's penicillin and related intermediate production has consolidated in a small number of Chinese facilities over the past two decades.

A formal investigation, if it proceeds, could bring several outcomes for buyers to track:

• Closer scrutiny of pricing practices among dominant antibiotic ingredient exporters.

• Potential trade measures or import conditions tied to supply chain transparency.

• Increased pressure on European manufacturers to explore alternative sourcing regions.

What New Chemicals Sector Rules Could Mean

While details remain under discussion, rules modeled on the Critical Medicines Act framework would likely push toward diversification requirements, stockpiling incentives or preferential treatment for non-Chinese and non-Indian suppliers.

Procurement teams sourcing intermediates and APIs should expect this to unfold gradually rather than as a single sweeping regulation. A few likely directions include:

• Diversification mandates: Requirements for pharmaceutical manufacturers to demonstrate multiple sourcing regions for critical ingredients.

• Strategic reserves: Incentives for stockpiling key antibiotics and other essential API categories within EU borders.

• Domestic production support: Funding or tax measures aimed at reviving European API manufacturing capacity that has largely shifted to Asia.

How China and India Came to Dominate This Market

China and India built their dominance in API and intermediate production over decades through lower production costs, large scale chemical manufacturing infrastructure and consistent government support for the sector. Europe's own capacity shrank as manufacturing shifted eastward in pursuit of cost efficiency.

That consolidation created real cost advantages for buyers for years, but it also concentrated risk. Disruptions at a handful of facilities, whether from regulatory action, environmental crackdowns or logistics bottlenecks, can ripple through global medicine supply almost immediately.

What This Means for Procurement and Sourcing Teams

Buyers who currently source APIs or key intermediates from Chinese or Indian suppliers should start thinking now about how new EU rules might affect contract terms, pricing or approved supplier lists. This does not mean an abrupt break from existing relationships, but it does suggest gradual diversification pressure building over the next few years.

Practical steps worth considering include:

• Reviewing supplier concentration across current API and intermediate contracts.

• Identifying alternative manufacturing regions, including within Europe, that could serve as backup sources.

• Watching for EU funding programs aimed at supporting domestic or allied API production.

Regulatory Momentum Beyond the Critical Medicines Act

The Critical Medicines Act was never framed as a standalone measure. It was widely understood as a first step in a broader effort to address supply chain fragility exposed during recent years of global disruption. Extending similar thinking into the chemicals sector fits that trajectory rather than representing a surprise pivot.

Trade groups, manufacturers and individual companies like Sandoz pushing for formal investigations suggest this issue has moved from background policy discussion to active industry pressure. That shift often precedes faster regulatory movement.

What Buyers Should Do Now

The path from policy discussion to enforceable rules can take time, but the direction is becoming clearer. Buyers and traders in the pharmaceutical ingredient supply chain should treat this as an early signal rather than wait for final legislation before adjusting sourcing strategy.

Diversifying supplier relationships now, even modestly, positions procurement teams to adapt more smoothly if EU rules tighten faster than expected. Waiting until rules are finalized often means competing with the entire market for the same limited pool of alternative suppliers.

Ready to source Pharmaceutical ingredients from verified global suppliers? Explore competitive offers on our platform today.